Now Playing
|Videos|June 26, 2023
Importance of Early Referral and Diagnosis in Small-Cell Lung Cancer
Expert oncologists provide an overview of the landscape surrounding small-cell lung cancer and highlight the importance of early referral and diagnosis for overall patient outcomes.
Advertisement
Episodes in this series
Advertisement
Related to this article
The FDA has approved zidesamtinib in patients with locally advanced/metastatic ROS1+ NSCLC who received a prior ROS1 kinase inhibitor.
China's NMPA accepted a supplemental application expanding toripalimab's perioperative NSCLC indication to stage II-III disease.
An updated HARMONi analysis showed a consistent OS benefit with ivonescimab plus chemotherapy in EGFR-mutated NSCLC.
An OncLive workshop covered practice-changing ROS1- and ALK-directed data in NSCLC shared at ASCO 2026 and beyond.
Lung cancer experts discuss the optimal management of CNS disease in EGFR-mutated non–small cell lung cancer.
Laure-Anne Teuwen, MD, PhD, debates the real-world advantages of subcutaneous pembrolizumab.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The phase 3 OptiTROP-Lung06 trial showed a PFS improvement with sac-TMT plus pembrolizumab in PD-L1–negative NSCLC.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Zidesamtinib in Pretreated ROS1+ NSCLC
2
Dr Patel on the Unmet Need in EGFR+ Transformed Small Cell Lung Cancer
3
Dr Hoffmann on the Significance of Efficacy Data for Sonrotoclax Plus Zanubrutinib in MCL
4
Dr Cooper on Biomarker Selection for DLL3-Targeted Therapies in ES-SCLC
5